13F Holdings
中文EN

KRSA Korsana Biosciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1755237 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-264.6%
TTM EPS YoY169.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-42.2%
ROA-33.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets9.9%
Debt / equity0.00x
Current ratio10.42x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.65x
Accruals ratio-11.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$2.07M$2.00M$0$297,000$3.94M
R&D expense$959,000$286,000$1.51M$5.98M$37.64M
SG&A expense$6.09M$5.34M$8.13M$12.86M$20.62M
Operating income-$4.97M-$3.63M-$12.95M-$18.54M-$55.20M
Pretax income-$3.53M-$3.06M-$5.26M-$44.08M-$51.65M
Income tax$0$0$0$0$0
Net income-$3.53M-$3.06M-$5.26M-$44.08M-$51.65M
EBITDA——-$12.95M-$18.48M-$54.72M
EPS (basic)-1.11-1.21-2.25-20.28-1.32
EPS (diluted)-1.11-1.21-2.25-20.28-1.32
Weighted avg. shares (diluted)3.18M2.52M2.34M2.17M39.14M
Balance sheet
Cash & equivalents$154.13M$10.11M$7.57M$13.38M$53.96M
Receivables$1.00M$556,000$0$96,000$100,000
Current assets$154.60M$4.22M$8.02M$14.82M$55.46M
PP&E, net$0$0$0$0$65,000
Total assets$154.60M$9.57M$13.37M$18.08M$59.33M
Current liabilities$12.49M$725,000$2.09M$7.63M$11.09M
Short-term debt———$3.50M$3.50M
Total liabilities$13.03M$725,000$2.09M$7.63M$11.09M
Shareholders' equity-$33.97M$66,000$11.29M$10.45M$48.25M
Shares outstanding1.24M2.55M2.47M2.18M43.41M
Cash flow statement
Operating cash flow-$3.31M-$4.33M-$21.25M-$40.61M-$36.52M
Capital expenditure———$0$7,000
Free cash flow———-$40.61M-$36.52M
Investing cash flow—$0$10.40M$0$1.46M
Financing cash flow$3.32M$0$5.02M$29,000$30.79M
Depreciation & amortization——$0$65,000$472,000
Stock-based compensation$441,000$625,000$1.07M$6.25M$9.61M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.